RxDoctor Payments Data

Ashley Lance, APRN

Family · St Joseph, MONPI 1629323365

Payments from drug & device makers

$2,202in general payments, 2019–2025

Across 108 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$782
  • AbbVie$387
  • Astellas Pharma US Inc$155
  • Lilly USA, LLC$144
  • Novo Nordisk$135
  • Amgen$66
  • plus $533 from 19 others

What the payments were for

  • Food & beverage$2,19199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,202 in reported general payments places this provider in the 80th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$54,049
Medicare patients
310
Services billed
816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$63,701
FarxigaDapagliflozin Propanediol41$36,222
MounjaroTirzepatide11$15,650
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$15,334
LinzessLinaclotide18$13,414
Tresiba Flextouch U-100Insulin Degludec27$12,499
EliquisApixaban13$11,988
Fenofibrate42$7,968
ArexvyRsvpref3 Antigen/As01e/Pf18$5,360
JanuviaSitagliptin Phosphate12$4,379
Diclofenac Sodium-MisoprostolDiclofenac Sodium/Misoprostol14$3,158
Novolog FlexpenInsulin Aspart11$2,417
Gabapentin132$1,807
Rosuvastatin Calcium159$1,797
Pantoprazole Sodium110$1,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$135$63,70158 claims
AstraZenecaFarxiga, Breztri Aerosphere$782$51,55565 claims
Lilly USA, LLCMounjaro$144$15,65011 claims
AbbVieLinzess, Synthroid$387$14,54141 claims
PfizerEliquis$15$11,98813 claims
GSKArexvy$46$5,36018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,812 family providers in Missouri.

Other family in St Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →